ABSTRACT A double blind, crossover study was undertaken to determine whether non-specific hyperresponsiveness in subjects with asthma was reduced by long term treatment with sodium cromoglycate and, if so, whether this was related to change in lung function. Forty four adult asthmatic subjects (41 atopic, three non-atopic) entered the one year study at intervals staggered over six months. After a baseline period to ensure that asthma control was stable subjects entered the treatment period, during which they inhaled sodium cromoglycate 20 mg four times daily or matching placebo four times daily for 16 weeks each, in random order. Our study was undertaken to examine the hypothesis that long term administration of sodium cromoglycate could reduce non-specific bronchial hyperresponsiveness in subjects with chronic asthma. The relationship between change in airway obstruction and change in responsiveness was also examined to determine whether any observed effect was dependent on change in lung function. 664 group.bmj.com on May 1, 2017 -Published by http://thorax.bmj.com/ Downloaded from
the provocative concentration of histamine causing a 20% fall in FEV, (PC20H) was calculated.
The assessment included daily symptom score, morning and evening Airflometer readings and treatment; mean values for each treatment period and also for the final four weeks of each period were compared. There were no significant differences between placebo and sodium cromoglycate treatment for PC20H, FEV1, morning or evening flow meter readings, bronchodilator usage, or symptom scores for the group as a whole, for the 16 week period or for the final four weeks of each period. Thirteen subjects showed better morning and evening flow meter readings while taking sodium cromoglycate than while taking placebo and eight better readings with placebo than with sodium cromoglycate (p < 0-05). Improvement in lung function did not correlate with baseline lung function or baseline PC20H, or with features of atopy. These results suggest that long term sodium cromoglycate treatment does not alter non-specific bronchial responsiveness in adult asthmatic subjects.
Many drugs used for the symptomatic treatment of asthma have been shown in short term or single dose studies to modify both specific and non-specific airway hyperresponsiveness.'" This effect is seen acutely with ,B2 adrenoceptor agonists,3 7 , which nevertheless have not been shown to reduce airway responsiveness to histamine over a four week period.47 Two non-bronchodilator agents, inhaled sodium cromoglycate81l and inhaled corticosteroids,'2 have been reported to reduce non-specific airway hyperresponsiveness over longer periods of time. When the present study began no double blind, placebo controlled study examining the long term effect of sodium cromoglycate on airway hyperresponsiveness had been performed. While some circumstantial evidence, combined with a theoretical understanding of the drug's mode of action, 13"5 suggested that sodium cromoglycate could reduce non-specific hyperresponsiveness, most of the data supported this hypothesis only indirectly.89 [16] [17] [18] Most single and multiple dose studies of the effect of sodium cromoglycate on histamine hyperresponsiveness have not shown any appreciable protection.' [19] [20] [21] Two more recent double blind, placebo controlled studies'°22 failed to find a significant change in bronchial responsiveness to methacholine or histamine after treatment with sodium cromoglycate for two weeks.
Our study was undertaken to examine the hypothesis that long term administration of sodium cromoglycate could reduce non-specific bronchial hyperresponsiveness in subjects with chronic asthma. The relationship between change in airway obstruction and change in responsiveness was also examined to determine whether any observed effect was dependent on change in lung function. 664 Long term study of the effect ofsodium cromoglycate on non-specific bronchial hyperresponsiveness
Methods

SUBJECTS
Forty eight subjects with asthma (as defined by the American Thoracic Society23) entered the study. Twenty were male and 28 female, their ages ranging from 15 to 65 (mean 37) years. Twenty patients had first developed asthma before they were 10, and 11 at the age of 40 or more. All were non-smokers, although eight had smoked previously. Mean FEV1 was 2-271(72% predicted, range 37-103% predicted). The geometric mean PC20H was 037 (range 0-05-5-66) mg/ml. Most subjects had moderate asthma with symptoms requiring more than one form of treatment for control. Further clinical and lung function details are given in table 1.
STUDY DESIGN
The study was of double blind, randomised, placebo controlled crossover design. Subjects entered the trial at intervals staggered over six months, beginning in March, and the trial lasted one year for each subject. This year was divided into a baseline period (8 weeks), two treatment periods (each 16 weeks) and a washout period (12 weeks 
Results
Forty eight patients with asthma were admitted to the study and 40 were able to complete it. Three subjects dropped out during the baseline period (one through unrelated illness, two because of inability to attend the laboratory) and a further five subjects (three having placebo and two sodium cromoglycate) at the end of treatment 1 (one having cromoglycate, because of moderately severe asthma requiring frequent courses of oral corticosteroids and admission to hospital, and two due to inability to continue attending the laboratory).
Although subjects were randomly allocated to receive placebo or sodium cromoglycate first the resulting groups differed (p < 0.05) with respect to age at entry into the study ( FEV,-forced expiratory volume in one second; PC20H-provocative concentration of histamine causing a 20% fall in FEV,; SCG-sodium cromoglycate; %P-value expressed as a % of the predicted normal for sex, age, and height; URTI-upper respiratory tract infection.
group.bmj.com on May 1, 2017 -Published by http://thorax.bmj.com/ Downloaded from Long term study of the effect of sodium cromoglycate on non-specific bronchial hyperresponsiveness (17) for placebo. The mean PD20H did not, however, differ significantly between cromoglycate and placebo periods, the mean values with 95% confidence limits being 0 67 (0 07-6 6) and 0-62 (0-06-61)mg/ml respectively. Eight subjects had significantly better morning and evening flow meter readings during placebo than during cromoglycate periods. Several clinical indices were used to examine the possible differences between responders to cromoglycate and non-responders (table 4). The only significant difference was in age of onset of asthma, which was 15 (SD 4) years for responders and 24 (4) years non-responders (p < 0-01). 
Discussion
The findings of this study suggest that the administration of sodium cromoglycate to adults with asthma does not alter non-specific bronchial hyperresponsiveness during 16 weeks, a period in which therapeutic benefit could be expected to be seen. Improvement in lung function occurred in 13 of the 48 subjects, but even this group showed no difference in PC20H values between cromoglycate and placebo periods. The results concur with those of studies conducted over shorter periods, which have shown attenuation of the airway response to specific stimuli, such as allergen and cold air, but not to histamine or methacholine.10 20 27 The well established efficacy of sodium cromoglycate in the context of specific bronchial provocations, such as exercise,28 allergen 11 19 and cold air,27 along with its usefulness as a prophylactic agent in asthma,"l 17 18 has led to the speculation that it may reduce non-specific bronchial hyperresponsiveness. Data suggesting that long term administration of cromoglycate could reduce non-specific bronchial hyperresponsiveness first came from Altounyan in 1970,8 who documented a reduction in histamine responsiveness after two weeks' treatment 668 with the drug in one individual during the pollen season. Subsequently, Altounyan documented a similar reduction in histamine responsiveness in 10 subjects during the pollen season, despite no change in baseline FEV1.8 1 This effect probably results from prevention of the allergic reaction during the pollen season, which thus inhibits an allergen induced increase in non-specific bronchial responsiveness.29
Dickson9 has reported a one year trial of a combination of sodium cromoglycate and isoprenaline in 24 asthmatic children. The percentage fall in FEV1 in response to a single dose of histamine was less while they were taking sodium cromoglycate-isoprenaline than three to seven days after withdrawal. The study was neither blind nor placebo controlled, however, and possibly the ,B agonist was contributing to this effect. Silverman"8 could not detect any change in histamine responsiveness in a year long, placebo controlled and double blind, parallel study of cromoglycateisoprenaline compound in 53 asthmatic children. Of four more recent studies examining the effect of cromoglycate on non-specific responsiveness, three have not shown any benefit,' 10 22 while one found an increase in PC20H over six weeks, though the magnitude of the change was not stated. 30 The weight of evidence therefore indicates a role for cromoglycate in preventing the consequences of natural allergen exposure and of modifying the airway response to specific stimuli such as exercise and cold air, but does not confirm a direct effect in reducing non-specific responsiveness.
For the subgroup whose lung function improved with sodium cromoglycate there was no association between an improvement in lung function and a reduction in non-specific responsiveness as measured by PC20H. There was no difference in mean PC20H values between those who improved in lung function and those who did not, suggesting that baseline non-specific responsiveness is not a determinant of the therapeutic response to cromoglycate.
Although the results from this study concur with those from several single dose and short term studies, other possible reasons for a lack of change in PC20H should be considered. Firstly, while PC20H is highly reproducible over short periods,3' it is probably less reproducible over weeks and months.32 Detecting a significant change in non-specific responsiveness is therefore more difficult in studies of several months than in short term studies. In addition, using a drug that does not usually benefit all patients introduces the problem of a varying response, militating against a statistically significant change in PC20H for the whole group.
One of the aims of the staggered entry into the study over a six month period was to dilute any Jenkins, Breslin seasonal effect. More pollen sensitive subjects took sodium cromoglycate than placebo in spring by chance. The change in PC20H for this subgroup was no different from that of the pollen sensitive subjects taking placebo in spring, so allergen exposure seems an unlikely explanation for a lack of improvement in non-specific responsiveness in these subjects. Very few subjects were sensitive only to pollen, and for most common inhaled allergens exposure is year round in Sydney.
Ideally, to examine the effect of sodium cromoglycate on non-specific responsiveness, subjects having minimal asthma treatment would be most suitable, minimising treatment interaction as well as the fluctuations in lung function that occur in more severely affected subjects. Beclomethasone has been reported to reduce non-specific responsiveness,' 2 and may reduce the potential therefore for a further increase in PC20H; but there was no significant difference between change in PC20H in subjects taking beclomethasone and those who were not. Possibly the administration of oral corticosteroids to seven subjects during the placebo period prevented a fall in PC20 that would have resulted in a significant difference between mean PC20H values for the cromoglycate and placebo periods. Omission of the data for these subjects, however, does not result in a different outcome for PC20H change. Indeed, oral corticosteroids may not result in an improvement in non-specific airway reactivity except at very high doses.' 2 Finally, fluctuations in baseline lung function could possibly have contributed to the lack of change in PC20H during active treatment; but analysis of PC20H values after exclusion of all subjects with a greater than 10% variability in baseline FEV1 did not alter the outcome of the study. Several studies have documented a change in PC20H despite stable lung function.36"'2 Although the level of airways obstruction has a significant but in most studies26 33 weak relationship to non-specific responsiveness, it is probably not the major determinant of such responsiveness in asthma.
The results of the study show that the administration of sodium cromoglycate to subjects with chronic, stable asthma did not alter non-specific responsiveness to histamine during 16 weeks. PC20H did not change in subjects whose lung function improved significantly. 
